300 related articles for article (PubMed ID: 31204078)
1. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Liu JF; Gordon M; Veneris J; Braiteh F; Balmanoukian A; Eder JP; Oaknin A; Hamilton E; Wang Y; Sarkar I; Molinero L; Fassò M; O'Hear C; Lin YG; Emens LA
Gynecol Oncol; 2019 Aug; 154(2):314-322. PubMed ID: 31204078
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
5. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.
Colevas AD; Bahleda R; Braiteh F; Balmanoukian A; Brana I; Chau NG; Sarkar I; Molinero L; Grossman W; Kabbinavar F; Fassò M; O'Hear C; Powderly J
Ann Oncol; 2018 Nov; 29(11):2247-2253. PubMed ID: 30219915
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
8. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Tamura K; Hasegawa K; Katsumata N; Matsumoto K; Mukai H; Takahashi S; Nomura H; Minami H
Cancer Sci; 2019 Sep; 110(9):2894-2904. PubMed ID: 31348579
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
McDermott DF; Sosman JA; Sznol M; Massard C; Gordon MS; Hamid O; Powderly JD; Infante JR; Fassò M; Wang YV; Zou W; Hegde PS; Fine GD; Powles T
J Clin Oncol; 2016 Mar; 34(8):833-42. PubMed ID: 26755520
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
12. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
[TBL] [Abstract][Full Text] [Related]
13. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
[TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
15. A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
Park SJ; Chang SJ; Suh DH; Kong TW; Song H; Kim TH; Kim JW; Kim HS; Lee SJ
BMC Cancer; 2022 Jan; 22(1):28. PubMed ID: 34980026
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Liu JF; Herold C; Gray KP; Penson RT; Horowitz N; Konstantinopoulos PA; Castro CM; Hill SJ; Curtis J; Luo W; Matulonis UA; Cannistra SA; Dizon DS
JAMA Oncol; 2019 Dec; 5(12):1731-1738. PubMed ID: 31600397
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Hellmann MD; Kim TW; Lee CB; Goh BC; Miller WH; Oh DY; Jamal R; Chee CE; Chow LQM; Gainor JF; Desai J; Solomon BJ; Das Thakur M; Pitcher B; Foster P; Hernandez G; Wongchenko MJ; Cha E; Bang YJ; Siu LL; Bendell J
Ann Oncol; 2019 Jul; 30(7):1134-1142. PubMed ID: 30918950
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
Schilder RJ; Pathak HB; Lokshin AE; Holloway RW; Alvarez RD; Aghajanian C; Min H; Devarajan K; Ross E; Drescher CW; Godwin AK
Gynecol Oncol; 2009 Apr; 113(1):21-7. PubMed ID: 19162309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
